Hepatitis/MASH

Experimental hepatitis C medication treats genotypes 1 through 6.

Direct-acting antivirals may cause hepatitis B reactivation in patients with an HCV/HBV co-infection.

Top news of the day from across the health care landscape.

Patients risk the development of thyroid dysfunction from interferon alpha in patients with hepatitis C virus infection.

Ultrasound not deemed to be sufficiently sensitive to detect early stage liver cancer.

An estimated 107,000 veterans are currently undiagnosed or untreated for HCV.

Injection drug users carry a different set of challenges during treatment for hepatitis C virus.

Navigating prior authoization requirements for patients coinfected with hepatitis C and HIV remains a challenge.

Achieving global elimination of the virus starts with illicit drug users accessing curative hepatitis C virus treatments.

Top news of the day from across the health care landscape.

Autumn Bagwell, PharmD, BCPS, clinical pharmacist at Vanderbilt Specialty Pharmacy, discusses the components of an effective patient management program to optimize adherence.

Hepatitis C causes inflexible scar tissue to form in the liver.

Direct-acting antivirals can cure hepatitis C in most patients, but the drugs don’t eliminate complications, such as cirrhosis and liver cancer.

Viekira XR consists of three oral tablets taken once a day.

New data reveals only a portion of hepatitis C positive individuals receive treatment.

Top news of the day from across the health care landscape.

Gilead Sciences maker of hepatitis C virus blockbusters Sovaldi, Harvoni, and, most recently, Epclusa has come under increasing scrutiny for declining revenues, both in the near-term and beyond.

Top news of the day from across the health care landscape.

FDA advises nucleic acid tests to screen for hepatitis B virus.

Top news of the day from across the healthcare landscape.

Organ rejection is caused by donor dendritic cells being rapidly replaced by the recipient’s cells.

Hepatitis C testing is often skipped during baby boomer physician office visits.

The impact of antiviral hepatitis C drugs in day-to-day life will be examined.

Patients taking mediations for both HIV and HCV must be closely monitored for drug-drug interactions.

Study will be the first to evaluate the role of metformin on liver fibrosis in HCV-HIV co-infected and HCV mono-infected patients.

Direct acting antiviral drugs may increase adverse events after liver transplantation.

Altered flora from antibiotics could affect future drug response and susceptibility to side effects.

Work advances on drug for hepatitis B the rare disease alpha-1 antitrypsin deficiency.

Liver stiffness drops through sustained virological response at 24 weeks with hepatitis C antiviral drug regimen.

New system allows direct absorption of a drug and prevents first past metabolism.